System validation has changed. Has your approach?
For decades, validation meant documentation. Today it means proving your systems are safe, traceable and auditable — with exactly the level of evidence each regulation requires, no more and no less. At OqoTech, we've spent 15 years adapting to these changes before they reach your inspections.
Trusted by over 100 leading companies
We are not a consultancy from the past that has added 'AI' to its presentation.
There are consultancies that have been doing validation the same way for twenty years. They know the regulations, have their templates, deliver their documents. And they work. Until a CSA-based inspection comes along, or a cloud system the vendor updates every two weeks, or a machine learning algorithm integrated into the production line. We start from the same regulatory rigor as always — FDA, EMA, AEMPS, GAMP 5 — but apply it with today's criteria and tools. The result is validation that complies, that can be defended, and that doesn't paralyze operations.
The industry has changed three times in twenty years. Those who haven't adapted are paying for it now.
The origin of electronic records
When the FDA published 21 CFR Part 11, the challenge was clear: prove that electronic records were as reliable as paper. Companies built enormous validation systems, with hundreds of pages of documentation per project. It was necessary then. In many organizations, it still works the same way.
GAMP 5 and the risk-based approach
A guide that tried to bring order: categorize systems, adjust documentation levels to real risk, stop validating a data entry form with the same intensity as a critical process control system. It was a huge step forward. But it also created a new layer of bureaucracy that many teams still haven't managed to handle well.
CSA and the paradigm shift
The FDA published the Computer Software Assurance guidance and changed the rules of the game. The message was direct: stop documenting for documentation's sake. Demonstrate that the system works for what it needs to work for, with risk-based testing and real evidence instead of accumulated paper.
AI, cloud and systems that change on their own
The industry is moving toward the cloud, toward SaaS, toward systems the vendor updates with increasing frequency and agility, toward artificial intelligence embedded in manufacturing and quality control processes. Most validation programs haven't evolved at the same pace.
The origin of electronic records
When the FDA published 21 CFR Part 11, the challenge was clear: prove that electronic records were as reliable as paper. Companies built enormous validation systems, with hundreds of pages of documentation per project. It was necessary then. In many organizations, it still works the same way.
GAMP 5 and the risk-based approach
A guide that tried to bring order: categorize systems, adjust documentation levels to real risk, stop validating a data entry form with the same intensity as a critical process control system. It was a huge step forward. But it also created a new layer of bureaucracy that many teams still haven't managed to handle well.
CSA and the paradigm shift
The FDA published the Computer Software Assurance guidance and changed the rules of the game. The message was direct: stop documenting for documentation's sake. Demonstrate that the system works for what it needs to work for, with risk-based testing and real evidence instead of accumulated paper.
AI, cloud and systems that change on their own
The industry is moving toward the cloud, toward SaaS, toward systems the vendor updates with increasing frequency and agility, toward artificial intelligence embedded in manufacturing and quality control processes. Most validation programs haven't evolved at the same pace.
At OqoTech we've been following this evolution closely for 15 years. Not because we read it in a guide, but because we've lived it on real projects, with real clients, facing real inspectors who have also had to adapt.
Your problem depends on your role. So does our answer.
Quality Manager
Validation documentation has changed. So have we.
The traditional approach — a protocol for everything, evidence for everything, files no one reads again — is being replaced by something more demanding in what matters and lighter in what doesn't. FDA inspectors are no longer looking for folders full of paper. They're looking for risk understanding, documented judgment, and evidence that the system does what it's supposed to do. At OqoTech, we work with you to build that evidence solidly: from qualifying a laboratory instrument to fully validating an ERP. Documentation that an inspector can follow without asking awkward questions.
Regulatory Affairs Manager
Agencies have evolved. So have their expectations.
FDA has been talking about CSA since 2022. EMA updates Annex 11 with increasingly demanding data integrity criteria. COFEPRIS and ANVISA are progressively aligning with international standards. Meanwhile, your company operates in multiple markets with requirements that don't always point in the same direction. We know those differences because we manage them on real projects. We help you build a validation program compatible with all the jurisdictions where you operate, updated with current regulations and ready for what's coming.
Technical Director
Systems have changed. Validation must change with them.
Ten years ago you validated systems installed on your own servers, with versions you controlled and changes you planned. Today you validate SaaS the vendor updates, cloud platforms, APIs connecting systems from different manufacturers, and equipment with firmware no one has touched since it arrived. That requires a different approach. We know how to adapt GAMP 5 and CSA criteria to modern technology environments, and integrate validation into implementation projects from the start — not as a last-minute requirement.
IT Manager
Change management in validated systems can no longer be a bottleneck.
When systems were hosted on your servers and you controlled the changes, change control made sense as designed. Now your SaaS vendor continuously releases updates, security patches require immediate intervention, and cloud infrastructure has changed traditional system administration and data integrity assurance. We help you establish agile, traceable change management processes that can be defended in an inspection.
Fifteen years adapting. Three things that set us apart today.
Specialization that evolves
We don't do general quality audits or generic training. We do computerized systems validation, and we've been doing it for 15 years while regulations, systems, and inspector expectations changed around us. That capacity for adaptation is what our clients value most when they have a complex inspection ahead.
AI applied to real work
Artificial intelligence has arrived in validation just as it arrived earlier in manufacturing and quality control. At OqoTech we use it to analyze risks faster, generate more precise documentation, and detect inconsistencies before an inspector finds them. Not as a substitute for expert judgment, but as a tool to take that judgment further.
Presence in Spain and LATAM
We work in Spain, Mexico, Colombia, Panama, Costa Rica and Argentina, among others. We know the regulatory agencies of each market because we've worked in front of them. If your company operates in multiple countries, you don't need to explain the differences to us — we know them.
We work in the sectors where system validation is not optional.
The pharmaceutical industry, medical device manufacturers, biotechnology organizations, and CROs share a common denominator: their computer systems are part of the product. A software error is not a technical problem — it's a regulatory, quality and, ultimately, patient safety problem.
Pharmaceutical industry
Drug manufacturers, both innovative and generic, that need systems validated under 21 CFR Part 11, EU Annex 11 or both.
Medical devices
Companies under MDR and FDA QSR that need to integrate software validation into their quality management system without it being an operational burden.
Biotechnology and ATMPs
Organizations with highly complex processes where data integrity is not optional and systems must withstand the most demanding scrutiny.
Clinical research
CROs and clinical units managing trial data under GCP that need their systems to comply with 21 CFR Part 11 and European regulations.
The next inspection will ask questions that inspections five years ago didn't ask.
If your validation program hasn't evolved at the same pace as your systems and current regulatory expectations, now is the best time to review it — before an inspector does. Tell us where you stand. No sales presentations, no generic proposals. A direct conversation with someone who knows your problem.
Talk to a consultantStay up to date on regulatory compliance
Receive articles, guides and updates on GxP validation, data integrity and regulatory technology.
No spam. Unsubscribe at any time.
Your data will be processed by TECH & PROCESS SL to send you our newsletters. The legal basis is your consent, which you may withdraw at any time. Your data will not be shared with third parties. More information in our privacy policy.